These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15372744)
21. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
23. Endostatin: are the 2 years up yet? Schellens JH; Ratain MJ J Clin Oncol; 2002 Sep; 20(18):3758-60. PubMed ID: 12228194 [No Abstract] [Full Text] [Related]
24. The promise of anti-angiogenic cancer therapy. Oehler MK; Bicknell R Br J Cancer; 2000 Feb; 82(4):749-52. PubMed ID: 10732738 [No Abstract] [Full Text] [Related]
25. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Crawford Y; Ferrara N Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058 [TBL] [Abstract][Full Text] [Related]
26. Use of angiogenesis inhibitors in tumour treatment. Fayette J; Soria JC; Armand JP Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233 [TBL] [Abstract][Full Text] [Related]
27. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. Ledzewicz U; Schättler H J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982 [TBL] [Abstract][Full Text] [Related]
28. Cancer 'cure' article stirs up hot debate. Wadman M Nature; 1998 May; 393(6681):104-5. PubMed ID: 9603508 [No Abstract] [Full Text] [Related]
29. A comparison of antiangiogenic therapies for the prevention of liver metastases. Mi J; Sarraf-Yazdi S; Zhang X; Cao Y; Dewhirst MW; Kontos CD; Li CY; Clary BM J Surg Res; 2006 Mar; 131(1):97-104. PubMed ID: 16242720 [TBL] [Abstract][Full Text] [Related]
31. [Angiogenic mechanisms in cancer]. Bjerkvig R Tidsskr Nor Laegeforen; 2000 Nov; 120(29):3501. PubMed ID: 11188372 [No Abstract] [Full Text] [Related]
32. Metronomic chemotherapy: teaching old drugs new tricks? Vogelzang N Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217 [No Abstract] [Full Text] [Related]
33. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. D'Onofrio A; Gandolfi A Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598 [TBL] [Abstract][Full Text] [Related]
36. American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer. Duda DG IDrugs; 2007 Jun; 10(6):366-9. PubMed ID: 17641996 [No Abstract] [Full Text] [Related]
37. Antiangiogenesis: new frontiers in therapeutic development. LaMontagne KR Angiogenesis; 2005; 8(4):285-7. PubMed ID: 16400519 [No Abstract] [Full Text] [Related]
38. Molecular mechanisms of tumor vascularization. Auguste P; Lemiere S; Larrieu-Lahargue F; Bikfalvi A Crit Rev Oncol Hematol; 2005 Apr; 54(1):53-61. PubMed ID: 15780907 [TBL] [Abstract][Full Text] [Related]
39. Triggering tumor immunity through angiogenesis targeting. Jinushi M; Dranoff G Clin Cancer Res; 2007 Jul; 13(13):3762-4. PubMed ID: 17606704 [No Abstract] [Full Text] [Related]